ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1733

Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium

Anna Jonsson1, Carlos Donado2, Emma Gomez-Rivas1 and Michael Brenner3, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2022

Keywords: complement, Fibroblasts, Synovial, rheumatoid arthritis, Synovitis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. Most research has focused on CD4 T cells, but we have found that CD8+ T cells are strikingly abundant in inflamed RA synovium and make more IFNγ and nearly as much TNF as their CD4 T cell counterparts. We have recently identified a new effector CD8+ T cell population abundant in inflamed RA synovium and in other inflamed tissues. Unlike cytotoxic T lymphocytes, these synovial CD8+ T cells have low cytotoxic potential, with low levels of granzyme B and perforin. Instead, these CD8+ T cells expresses high levels of granzyme K (GzmK), a protease that does not cleave caspases. The function of GzmK in inflamed synovium and other tissues is unclear. Here, we describe that GzmK activates a new complement pathway, thereby activating an innate immune cascade with numerous pro-inflammatory effects on surrounding cells.

Methods: We incubated recombinant enzymatically active GzmK with serum-purified complement C2, C3, and/or C4 to investigate the molecular effects of GzmK on complement proteins. We measured cleavage of C2, C3, and C4 using Western blots. We analyzed complement gene expression in a published dataset of bulk RNA-sequencing (RNA-seq) data from fibroblasts, macrophages, B cells, and T cells sorted from human RA and osteoarthritis synovial tissue samples. In addition, we stimulated cultured RA synovial fibroblasts with recombinant IFNγ or TNF for 24 hours, performed low-input RNA-seq, and compared expression levels of selected complement genes. Functional assays include flow cytometry to measure phosphorylation of mammalian target of rapamycin (mTOR) as well as ELISAs to measure cytokine production.

Results: GzmK cleaves C4 to C4b and C2 to C2a to form an active C3 convertase (C4b + C2a) that cleaves C3 to C3a and C3b. Further, we show that synovial fibroblasts, important drivers of chronic inflammation in RA, are the dominant cellular source of complement components in the synovium. IFNγ and TNF, cytokines abundantly produced by CD8 T cells, drive fibroblasts to synthesize and release C2, C3, and C4. Strikingly, we show that GzmK cleaves C4 and C2 secreted by fibroblasts, eliciting formation of an extracellular C3 convertase that generates C3a and C3b. Unlike recent studies of murine synovial fibroblasts, we do not find that human synovial fibroblasts respond to C3a stimulation. Instead, our findings support a three-cell model for complement activation, where CD8 T cell-derived GzmK can act extracellularly on fibroblast-derived complement components, generating C3a and C3b that then acts on other nearby cells, such as macrophages and mast cells (Figure 1).

Conclusion: GzmK activates a novel complement pathway that is independent of the classical, alternative, and lectin pathways of complement activation, and the C3a and C3b that GzmK generates may perpetuate tissue inflammation in RA and other diseases.

Supporting image 1

Figure 1. Proposed model of Granzyme K-activated complement pathway in RA. Created with BioRender.com.


Disclosures: A. Jonsson, Amgen; C. Donado, None; E. Gomez-Rivas, None; M. Brenner, GSK, 4FO Ventures, Mestag Therapeutics.

To cite this abstract in AMA style:

Jonsson A, Donado C, Gomez-Rivas E, Brenner M. Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/granzyme-k-elicits-a-new-pathway-for-complement-activation-in-ra-synovium/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/granzyme-k-elicits-a-new-pathway-for-complement-activation-in-ra-synovium/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology